Global Beri Beri Treatment Market - 2022-2029

Global Beri Beri Treatment Market - 2022-2029

Market Overview

The global beri beri treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Vitamin B1 deficiency is a disease in which the body does not have enough of the vitamin (thiamin). A poor diet or alcoholism most commonly brings on beriberi. Loss of appetite, weakness, limb pain, shortness of breath, and swollen feet or legs are some of the symptoms.

Market Dynamics

The factors influencing the global beri beri treatment market are the increasing research and development and the growing prevalence of thiamine deficiency.

The increasing research and development is expected to drive the market growth in the forecast period

Edema, breathlessness, muscle weakness, and beriberi, a sheep-like gait pattern, are all symptoms of thiamine deficiency. Thiamine is a water-soluble vitamin that cannot be stored in significant quantities. Surgery, fasting, strenuous activity, fever, sepsis, pregnancy, breastfeeding, adolescent growth, and anorexia increase thiamine requirements. Acute or fulminant beriberi can result from an increased requirement for thiamine or a decrease in thiamine consumption after a gastrectomy, with aging patients being more susceptible. Beriberi can develop many years after gastrectomy and go unnoticed by doctors, resulting in treatment delays. It's critical to recognize and treat beriberi as soon as possible, as well as a rule out other possible diagnoses. Beriberi is a nutritional complication of gastric surgery that has life-threatening clinical implications. Because thiamine is absorbed in the duodenum and proximal jejunum, patients with a total gastrectomy, Billroth II gastrectomy, or Roux-en-Y diversion are at an increased risk. Beriberi has also been reported after laparoscopic sleeve gastrectomy, gastroplasty, and laparoscopic adjustable gastric banding. After upper gastrointestinal surgery, patients frequently have subclinical thiamine deficiency. Thiamine deficiency causes glucose metabolism problems, reduced oxygen delivery by red blood cells, cardiac dysfunction, axonopathy, neurotransmission failure, and neuron death. Moreover, for men and women, the Recommended Dietary Intake (RDI) of oral thiamine is 1.2 mg and 1.1 mg, respectively, and the daily Estimated Average Requirement (EAR) is 1.0 mg and 0.9 mg. Sensorimotor peripheral neuropathy, Wernicke encephalopathy, Korsakoff psychosis (dry beriberi), cardiac failure, edema, and arrhythmia are symptoms of thiamine deficiency (wet beriberi).

The side effects associated with beriberi treatment are expected to hamper the market growth

The side effects associated with thiamine are severe allergic reaction to heat (anaphylaxis), discoloration of the skin, sweating \srestlessness, hives with rapid skin swelling and itching, inflammation of the lungs (pulmonary edema), weakness, nausea throat constriction.

There are no known serious interactions between thiamine and other medications. The following are examples of thiamine interactions moderate azithromycin \sclarithromycin, erythromycin lactobionate, erythromycin stearate, erythromycin base erythromycin ethylsuccinate, and roxithromycin. At least 69 different drugs have mild interactions with thiamine. Hence, the side effects and interactions associated with thiamine are expected to hamper market growth.

COVID-19 Impact Analysis

Thiamine as adjunctive therapy may improve survival in COVID-19 patients who are critically ill. Additionally, it was linked to a reduced risk of thrombosis. Systemic thiamine administration may be considered part of COVID-19 management during ICU admission. The role of thiamine in COVID-19 patients is still unknown; however, it has been studied extensively in critically ill patients. Moskowitz et al. found that thiamine was linked to significantly lower lactate levels, serum creatinine, and a possible reduction in 30-day mortality in a randomized controlled trial. In addition, thiamine administration within 24 hours was linked to improved lactic acid clearance and lower 28-day mortality in critically ill patients with septic shock. Hence, the increasing demand for thiamine during covid-19 is expected to positively impact the market.

Segment Analysis

Wet Beriberi segment is expected to dominate the market growth

Thiamine deficiency with cardiovascular involvement is referred to as wet beriberi. There are three stages to the chronic form of wet beriberi. Peripheral vasodilation occurs in the first stage, resulting in a high cardiac output state. This causes salt and water retention in the kidneys, mediated by the renin-angiotensin-aldosterone system. The kidneys detect a relative volume loss as the vasodilation progresses and respond by conserving salt. Fluid is absorbed into the circulatory system as a result of salt retention. Edema of the dependent extremities occurs as a result of fluid overload.

Acute fulminant cardiovascular beriberi, also known as Shoshin beriberi, is a faster form of wet beriberi. The heart is the most commonly injured organ, and rapid deterioration results from the heart muscle's inability to meet the body's demands due to its injury. Edema may not be present in this case. Instead, cyanosis of the hands and feet, tachycardia, dilated neck veins, restlessness, and anxiety are experienced. Because systemic vasoconstriction is restored before the heart muscle recovers, thiamine treatment causes low-output cardiac failure. Vitamin B1 therapy can help with the diagnosis and treatment of wet beriberi. It is widely accepted that patients suspected of having thiamine deficiency should receive therapeutic thiamine administration.

Geographical Analysis

North America region is expected to hold the largest market share in the global beri beri treatment market

Due to high healthcare costs and high-quality medical facilities, the vast majority of the population is covered by insurance. The presence of key players in the market is expected to drive market growth. For instance, the company Fresenius Kabi USA’s thiamine hydrochloride injection, USP, is effective for treating berberi.

Competitive Landscape

The global beri beri treatment market is moderately competitive. Some of the key players in the market are Fresenius Kabi USA, LLC, GlaxoSmithKline plc, Parex Pharmaceuticals Pvt. Ltd., Solgar, EZ Melts, Bulk Supplements, DSM, AdvaCare Pharma.

Fresenius Kabi USA

Overview: Fresenius Kabi is a global healthcare company specializing in infusion, transfusion, and clinical nutrition medicines and technologies. The company has headquarters in Illinois, United States, founded in 1912.

Product Portfolio: Thiamine hydrochloride injection, USP is a sterile solution of thiaminehydrocholride in water for injection for intramuscular (IM) or slow intravenous (IV) administration. It is effective for the treatment of berberi.

Why Purchase the Report?

Visualize the composition of the global beri beri treatment market segmentation by type, drug type , and end user, highlighting the key commercial assets and players.

identify commercial opportunities in global beri beri treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global beri beri treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global beri beri treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers